Need professional-grade analysis? Visit stockanalysis.com
$270.56M
N/A
N/A
N/A
SAB Biotherapeutics Inc (SABS) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $3.99, up 4.72% from the previous close.
Over the past year, SABS has traded between a low of $1.50 and a high of $4.58. The stock has gained 166.0% over this period. It is currently 12.9% below its 52-week high.
SAB Biotherapeutics Inc has a market capitalization of $270.56M.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Side-by-side comparison against top Healthcare peers.